Actively Recruiting
Imaging of Solid Tumors Using 18F-TRX
Led by Rahul Aggarwal · Updated on 2025-07-18
56
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
Sponsors
R
Rahul Aggarwal
Lead Sponsor
U
United States Department of Defense
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
CONDITIONS
Official Title
Imaging of Solid Tumors Using 18F-TRX
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Advanced solid tumor malignancy meeting one of the following:
- Cohort 1: Any solid tumor with at least 3 metastatic lesions on conventional imaging
- Cohort 2: WHO grade 3 or 4 glioma; locally advanced or metastatic clear cell renal cell carcinoma with at least 3 metastatic lesions; metastatic castration-resistant prostate cancer with at least 1 metastatic lesion on imaging
- Ability to understand and willing to sign informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Negative pregnancy test within 72 hours of baseline procedures for women of childbearing potential
- Absolute neutrophil count greater than 1.5 x 10^6/L
- Platelets greater than 75,000 x 10^6/L
- Hemoglobin greater than 8 g/dL
- Total bilirubin less than 1.5 times the upper limit of normal
- AST (SGOT) less than 2.5 times upper limit of normal (less than 5 times if liver metastases present)
- ALT (SGPT) less than 2.5 times upper limit of normal (less than 5 times if liver metastases present)
- Creatinine clearance greater than 50 ml/min calculated by Cockcroft-Gault equation
You will not qualify if you...
- Any condition or social circumstance that would impair ability to comply with study procedures
- Use of strong inhibitors or inducers of CYP3A4
- Uncontrolled active infection or other medical conditions that would prevent safe participation
- Pregnant individuals
- Breastfeeding or chestfeeding individuals
- Women of childbearing potential must have a negative pregnancy test before scans
- Females considered not of childbearing potential if postmenopausal for at least 12 months or surgically sterilized (hysterectomy and/or bilateral oophorectomy)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
M
Maya Aslam
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here